Bionano Genomics BNGO
Bionano Genomics reported a net loss of $6.45 million for the three months ended Sep 30, 2026.
Bionano Genomics (BNGO) filed a 10-Q with the SEC on Nov 10, 2026, 4:11 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001411690-26-000059
- Revenue was $8.28 million for the three months ended Sep 30, 2026.
- Diluted EPS was -$0.54 for the three months ended Sep 30, 2026.
- Cash and equivalents were $4.36 million as of Sep 30, 2026.
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
